RE:RE:RE:RE:RE:Wound healing:prophetoffactz wrote: "There is a difference in being secretive and having a strategy. Here's where customer focus is key. No use building a better mousetrap if no one is interested."
Hard to know the strategy if it is secretive. How can they tell you the strategy if it is secretive?
The first goal in biotech is also to prove that you even have better mousetrap. CZO has clearly undertaken work to investigate if its avenanthramide and beta glucan can produce any interesting results as an injectable. The injectable abstract concluded: "A better understanding of the differing mechanisms driving these naturally derived therapeutics may lead to improved patient wound outcomes". Clearly more work can be done to define avenanthramide and beta glucan individually as an injectable. Then in combination using PGX as a carrier? Include PGX-YBG too given the importance of macrophages? There may be much experimentation ahead.
The future course will depend on the evolution of the science which can be trial-and-error as Dr. Ask has said about the fibrosis studies. It is difficult to understand the next step until the first is completed. Speculating on the outcome can be foolish for development stage science; especially concernng timelines. CZO has also investigated wound dressings. Perhaps, untimatly, a wound dressing will be used with an injectable. CZO has more work to do to define what it has. Entering a deal before you even know what you have would be Mickey Mouse. CZO is defining the value it can bring to the table as PGX and avenanthramide production is also scaled-up adding value.
LOL. You can have a strategy to partner up for research and development and be secretive on the details of product development.